Biostage Esophageal Implant is under clinical development by Harvard Apparatus Regenerative Technology and currently in Phase I for Esophageal Atresia. According to GlobalData, Phase I drugs for Esophageal Atresia does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Biostage Esophageal Implant LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Biostage Esophageal Implant overview
Stem cell therapy is under development for the treatment of esophageal atresia in pediatrics and esophageal cancer. It is administered by intraesophageal route as implant. The therapeutic candidate comprises of a synthetic tubular scaffold seeded with autologous adipose-derived mesenchymal stem cells (aMSCs) and is being developed based on Cellframe technology.
Harvard Apparatus Regenerative Technology overview
Harvard Apparatus Regenerative Technology (Harvard Apparatus), formerly Biostage, operates as a biotechnology company. The company carries out the business of development and commercialization of regenerated organs for human transplant. It develops bioengineered organ implants based on its Cellframe technology which combines biocompatible scaffold with a patient’s own stem cells to create Cellspan organ implants. Harvard Apparatus’s pipeline offerings include Cellspan bronchial implants, Cellspan esophageal implants and Cellspan tracheal implants. Its clinical stage product candidates include cell isolation and expansion; cell biology and seeding of cells on the scaffold. The company has operations across Germany, the US, Sweden and the UK. Harvard Apparatus is headquartered in Holliston, Massachusetts, the US.
For a complete picture of Biostage Esophageal Implant’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
